Indeed, knockdown of CtBP1 via siRNA or inhibition of its dehydrogenase activity through MTOB treatment significantly reduces PH-Fib proliferation and normalizes aberrant metabolic phenotypes, similar to the effects observed in cancer therapy where CtBP1 inhibition upregulates the expression of cyclin-dependent kinase inhibitors (p15 and p21) and proapoptotic genes (NOXA and PERP) [65]. This evidence concerns the gene CTBP1 and cancer.